SCHEMBL19359551

SCHEMBL19359551

Nc1cc(C(CCNS(=O)(=O)c2ccccc2)c2ccccc2)c(N=Nc2ccc(Cl)cc2)c(N)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.39
▸ TP53 P04637 3/20 0.39
▸ GAA P10253 3/20 0.39
▸ MEN1 O00255 3/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ PKM P14618 1/20 0.37
▸ ALDH1A1 P00352 3/20 0.36
▸ LMNA P02545 5/20 0.36
▸ NPSR1 Q6W5P4 2/20 0.36
▸ XBP1 P17861 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ HTT P42858 2/20 0.36
▸ RECQL P46063 1/20 0.36
▸ TBXA2R P21731 3/20 0.35
▸ TBXAS1 P24557 3/20 0.35
▸ MPO P05164 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ PTPN1 P18031 1/20 0.35
▸ PTPN6 P29350 1/20 0.35
▸ PTPN11 Q06124 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19359549 1.00 MAPT (0.39) MAPTTP53GAAMEN1KMT2A
SCHEMBL22406467 0.82 EPHX2 (0.48) MAPTMEN1KMT2ARECQLALOX5
SCHEMBL22406468 0.82 EPHX2 (0.48) MAPTMEN1KMT2ARECQLALOX5
SCHEMBL19380833 0.82 EPHX2 (0.48) MAPTMEN1KMT2ARECQLALOX5
SCHEMBL22406664 0.82 MPO (0.54) MAPTMEN1KMT2ARECQLMPO
SCHEMBL19380987 0.82 MPO (0.54) MAPTMEN1KMT2ARECQLMPO
SCHEMBL19380989 0.80 PKM (0.45) TP53GAAPKMALDH1A1LMNA
SCHEMBL19359262 0.80 PKM (0.45) TP53GAAPKMALDH1A1LMNA
SCHEMBL19359500 0.78 CYP3A4 (0.47) MAPTGAAMEN1KMT2AALDH1A1
SCHEMBL19359499 0.78 CYP3A4 (0.47) MAPTGAAMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11008317-B2 Triazolopyridine inhibitors of myeloperoxidase and/or EPX BRISTOL-MYERS SQUIBB COMPANY (US) 2021-05-18 — — US disclosed
US-20200291016-A1 TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX BRISTOL MYERS SQUIBB CO (US) 2020-09-17 — — US disclosed
WO-2017161145-A1 TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX BRISTOL-MYERS SQUIBB COMPANY (US) 2017-09-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200291016-A1 TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX EPX, MPO, SERPINB1 MAPT 4328/4885TP53 4778/4885GAA 1103/4885
US-11008317-B2 Triazolopyridine inhibitors of myeloperoxidase and/or EPX EPX, MPO, SERPINB1 MAPT 4328/4885TP53 4778/4885GAA 1103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback